Skip to main content
Have a personal or library account? Click to login
Genotype-phenotype correlations in patients treated with acenocoumarol / Corelaţii genotip-fenotip la pacienţii trataţi cu acenocumarol Cover

Genotype-phenotype correlations in patients treated with acenocoumarol / Corelaţii genotip-fenotip la pacienţii trataţi cu acenocumarol

Revista Romana de Medicina de Laborator
Volume 22 (2014): Issue 3 (September 2014)
By: ,  ,  ,  ,   and    
Open Access
|Oct 2014
References

References

  1. 1. Wolkanin-Bartnik J, Pogorzelska H, Szperl M, Bartnik A, Koziarek J, Bilinska ZT. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. Pharmacogenet Genomics. 2013;23(11):611-8. DOI: 10.1097/ FPC.0000000000000004
    Open DOISearch in Google Scholar
  2. 2. Daly AK. Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med. 2009;1(1):10. DOI: 10.1186/gm10
    Open DOISearch in Google Scholar
  3. 3. Buzoianu AD, Trifa AP, Mureşanu DF, Crişan S. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med. 2012;16(12):2919-24. DOI: 10.1111/j.1582-4934.2012.01606.x
    Open DOISearch in Google Scholar
  4. 4. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000;28(11):1284-90.
    Search in Google Scholar
  5. 5. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106(1):135-40. DOI: 10.1182/blood-2005-01-0341
    Open DOISearch in Google Scholar
  6. 6. Pop TR, Vesa Ş, Trifa AP, Crişan S, Buzoianu AD. An acenocoumarol dose algorithm based on a South-Eastern European population. Eur J Clin Pharmacol. 2013;69(11):1901-7. DOI: 10.1007/s00228-013-1551-3
    Open DOISearch in Google Scholar
  7. 7. Anton AI, Cerezo-Manchado JJ, Padilla J, Perez-Andreu V, Corral J, Vicente V, et al. Novel associations of VKORC1 variants with higher acenocoumarol requirements. PLoS One. 2013;8(5):e64469. DOI: 10.1371/ journal.pone.0064469
    Open DOISearch in Google Scholar
  8. 8. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, et al; EU-PACT Group. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost. 2012;10(4):606-14. DOI: 10.1111/j.1538-7836.2012.04633.x
    Open DOISearch in Google Scholar
  9. 9. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1-16. DOI: 10.1016/j. clpt.2004.08.009
    Search in Google Scholar
  10. 10. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and their impact on the inter individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94(4):773-9.
    Search in Google Scholar
  11. 11. Montes R, de Gaona RE, Martinez-Gonzalez MA, Alberca I, Hermida J. The c._1639G4A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006;133(2):183-187. DOI: 10.1111/j.1365-2141.2006.06007.x
    Open DOISearch in Google Scholar
  12. 12. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. 2008;84(1):83-9. DOI: 10.1038/ sj.clpt.6100453
    Open DOISearch in Google Scholar
  13. 13. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155-66. DOI: 10.1378/chest.129.5.1155
    Open DOISearch in Google Scholar
  14. 14. Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics. 2008;9(9):1237-50. DOI: 10.2217/14622416.9.9.1237
    Open DOISearch in Google Scholar
  15. 15. Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, Stricker BH, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4):379-86. DOI: 10.1038/clpt.2008.294
    Open DOISearch in Google Scholar
  16. 16. Schalekamp T, Brassé BP, Roijers JFM, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006;80(1):13-22. DOI: 10.1016/j.clpt.2006.04.006
    Open DOISearch in Google Scholar
  17. 17. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on Warfarin Response during Initiation of Therapy. Blood Cells Mol Dis. 2009;43(1):119-128. DOI: 10.1016/j. bcmd.2009.01.019
    Search in Google Scholar
  18. 18. Pérez-Andreu V1, Roldán V, Antón AI, García-Barberá N, Corral J, Vicente V, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113(20):4977-9. DOI: 10.1182/ blood-2008-09-176222
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/rrlm-2014-0032 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624 (formerly 2284-5623)
Journal RSS Feed
Language: English, Romanian
Page range: 347 - 354
Submitted on: May 13, 2014
Accepted on: Aug 10, 2014
Published on: Oct 8, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Keywords:
Acenocoumarol,
CYP2C9,
INR,
VKORC1
Related subjects:
Life sciences,
Molecular biology

© 2014 Florentina Claudia Militaru, Ştefan Cristian Vesa, Sorin Crişan, Valentin Militaru, Adrian Pavel Trifa, Anca Dana Buzoianu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 22 (2014): Issue 3 (September 2014)
Previous article
Next article